These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

634 related articles for article (PubMed ID: 15627067)

  • 21. Peripheral blood stem cell support reduces the toxicity of intensive chemotherapy for children and adolescents with metastatic sarcomas.
    Hawkins DS; Felgenhauer J; Park J; Kreissman S; Thomson B; Douglas J; Rowley SD; Gooley T; Sanders JE; Pendergrass TW
    Cancer; 2002 Sep; 95(6):1354-65. PubMed ID: 12216105
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [High dose ifosfamide at 15 g/m2/cycle: a feasibility study in 10 patients].
    Baranzelli MC; Pichon F; Gourmel B; N'Guyen M; Deligny N; Demaille MC
    Bull Cancer; 1997 Feb; 84(2):141-6. PubMed ID: 9180836
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dana-Farber Cancer Institute studies in advanced sarcoma.
    Antman KH; Elias A
    Semin Oncol; 1990 Feb; 17(1 Suppl 2):7-15. PubMed ID: 2106162
    [TBL] [Abstract][Full Text] [Related]  

  • 24. High-dose ifosfamide in bone and soft tissue sarcomas: results of phase II and pilot studies--dose-response and schedule dependence.
    Patel SR; Vadhan-Raj S; Papadopolous N; Plager C; Burgess MA; Hays C; Benjamin RS
    J Clin Oncol; 1997 Jun; 15(6):2378-84. PubMed ID: 9196153
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Randomized comparison of granulocyte colony-stimulating factor versus granulocyte-macrophage colony-stimulating factor plus intensive chemotherapy for peripheral blood stem cell mobilization and autologous transplantation in multiple myeloma.
    Arora M; Burns LJ; Barker JN; Miller JS; Defor TE; Olujohungbe AB; Weisdorf DJ
    Biol Blood Marrow Transplant; 2004 Jun; 10(6):395-404. PubMed ID: 15148493
    [TBL] [Abstract][Full Text] [Related]  

  • 26. High-dose ifosfamide in the treatment of advanced soft tissue sarcomas.
    Tursz T
    Semin Oncol; 1996 Jun; 23(3 Suppl 7):34-9. PubMed ID: 8711500
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Preoperative hyperfractionated chemoradiation for locally recurrent rectal cancer in patients previously irradiated to the pelvis: A multicentric phase II study.
    Valentini V; Morganti AG; Gambacorta MA; Mohiuddin M; Doglietto GB; Coco C; De Paoli A; Rossi C; Di Russo A; Valvo F; Bolzicco G; Dalla Palma M;
    Int J Radiat Oncol Biol Phys; 2006 Mar; 64(4):1129-39. PubMed ID: 16414206
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Salvage surgical resection after high-dose ifosfamide (HDIF) based regimens in advanced soft tissue sarcoma (ASTS): a potential positive selection bias--a study of the Spanish group for research on sarcomas (GEIS).
    Maurel J; Buesa J; López-Pousa A; del Muro XG; Quintana MJ; Martín J; Casado A; Martínez-Trufero J; de Las Peñas R; Balañá C
    J Surg Oncol; 2004 Oct; 88(1):44-9. PubMed ID: 15384088
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A phase II study of cisplatin, doxorubicin, and ifosfamide with peripheral blood stem cell support in patients with skeletal osteosarcoma and variant bone tumors with a poor prognosis.
    Patel SR; Papadopolous N; Raymond AK; Donato M; Seong CM; Yasko AW; Lewis VO; Lin PP; Champlin R; Benjamin RS
    Cancer; 2004 Jul; 101(1):156-63. PubMed ID: 15222001
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
    Hagemeister FB
    Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A phase III trial of ifosfamide with or without cisplatin in carcinosarcoma of the uterus: A Gynecologic Oncology Group Study.
    Sutton G; Brunetto VL; Kilgore L; Soper JT; McGehee R; Olt G; Lentz SS; Sorosky J; Hsiu JG
    Gynecol Oncol; 2000 Nov; 79(2):147-53. PubMed ID: 11063636
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Treatment of advanced soft-tissue sarcomas using a combined strategy of high-dose ifosfamide, high-dose doxorubicin and salvage therapies.
    Leyvraz S; Herrmann R; Guillou L; Honegger HP; Christinat A; Fey MF; Sessa C; Wernli M; Cerny T; Dietrich D; Pestalozzi B;
    Br J Cancer; 2006 Nov; 95(10):1342-7. PubMed ID: 17031396
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Crossover randomized comparison of intravenous versus intravenous/oral mesna in soft tissue sarcoma treated with high-dose ifosfamide.
    Mace JR; Keohan ML; Bernardy H; Junge K; Niebch G; Romeis P; Thoma A; Wagner T; Mueller U; Demetri G; Baker LH
    Clin Cancer Res; 2003 Dec; 9(16 Pt 1):5829-34. PubMed ID: 14676103
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Ifosfamide in the treatment of soft-tissue sarcomas: experience at the West German Tumor Center, Essen.
    Schütte J; Kellner R; Seeber S
    Cancer Chemother Pharmacol; 1993; 31 Suppl 2():S194-8. PubMed ID: 8453697
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phase I trial of dose-escalated paclitaxel and carboplatin in combination with ifosfamide and filgrastim: preliminary results.
    Palackdharry CS
    Semin Oncol; 1996 Jun; 23(3 Suppl 6):78-83. PubMed ID: 8677455
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phase II study of induction chemotherapy with paclitaxel, ifosfamide, and carboplatin (TIC) for patients with locally advanced squamous cell carcinoma of the head and neck.
    Shin DM; Glisson BS; Khuri FR; Lippman SM; Ginsberg L; Diaz E; Papadimitrakopoulou V; Feng L; Francisco M; Garden A; Kies MS; Myers J; Clayman G; Hong WK
    Cancer; 2002 Jul; 95(2):322-30. PubMed ID: 12124833
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy of consolidation high-dose chemotherapy with ifosfamide, carboplatin and etoposide (HD-ICE) followed by autologous peripheral blood stem cell rescue in chemosensitive patients with metastatic soft tissue sarcomas.
    Schlemmer M; Wendtner CM; Falk M; Abdel-Rahman S; Licht T; Baumert J; Straka C; Hentrich M; Salat C; Hiddemann W; Issels RD
    Oncology; 2006; 71(1-2):32-9. PubMed ID: 17344669
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Phase II study of continuous-infusion high-dose ifosfamide in advanced and/or metastatic pretreated soft tissue sarcomas.
    Palumbo R; Palmeri S; Antimi M; Gatti C; Raffo P; Villani G; Toma S
    Ann Oncol; 1997 Nov; 8(11):1159-62. PubMed ID: 9426338
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial.
    Judson I; Verweij J; Gelderblom H; Hartmann JT; Schöffski P; Blay JY; Kerst JM; Sufliarsky J; Whelan J; Hohenberger P; Krarup-Hansen A; Alcindor T; Marreaud S; Litière S; Hermans C; Fisher C; Hogendoorn PC; dei Tos AP; van der Graaf WT;
    Lancet Oncol; 2014 Apr; 15(4):415-23. PubMed ID: 24618336
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prolonged 14-day continuous infusion of high-dose ifosfamide with an external portable pump: feasibility and efficacy in refractory pediatric sarcoma.
    Meazza C; Casanova M; Luksch R; Podda M; Favini F; Cefalo G; Massimino M; Ferrari A
    Pediatr Blood Cancer; 2010 Oct; 55(4):617-20. PubMed ID: 20589638
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 32.